1. Home
  2. DKL vs BLTE Comparison

DKL vs BLTE Comparison

Compare DKL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DKL
  • BLTE
  • Stock Information
  • Founded
  • DKL 2012
  • BLTE 2018
  • Country
  • DKL United States
  • BLTE United States
  • Employees
  • DKL N/A
  • BLTE N/A
  • Industry
  • DKL Natural Gas Distribution
  • BLTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • DKL Energy
  • BLTE Health Care
  • Exchange
  • DKL Nasdaq
  • BLTE Nasdaq
  • Market Cap
  • DKL 2.3B
  • BLTE 2.1B
  • IPO Year
  • DKL N/A
  • BLTE 2022
  • Fundamental
  • Price
  • DKL $46.14
  • BLTE $65.04
  • Analyst Decision
  • DKL Buy
  • BLTE Strong Buy
  • Analyst Count
  • DKL 4
  • BLTE 4
  • Target Price
  • DKL $44.25
  • BLTE $96.67
  • AVG Volume (30 Days)
  • DKL 60.8K
  • BLTE 65.6K
  • Earning Date
  • DKL 08-06-2025
  • BLTE 08-08-2025
  • Dividend Yield
  • DKL 9.67%
  • BLTE N/A
  • EPS Growth
  • DKL 7.97
  • BLTE N/A
  • EPS
  • DKL 2.98
  • BLTE N/A
  • Revenue
  • DKL $938,491,000.00
  • BLTE N/A
  • Revenue This Year
  • DKL $21.09
  • BLTE N/A
  • Revenue Next Year
  • DKL N/A
  • BLTE N/A
  • P/E Ratio
  • DKL $15.40
  • BLTE N/A
  • Revenue Growth
  • DKL N/A
  • BLTE N/A
  • 52 Week Low
  • DKL $34.59
  • BLTE $43.70
  • 52 Week High
  • DKL $46.35
  • BLTE $86.53
  • Technical
  • Relative Strength Index (RSI)
  • DKL 72.88
  • BLTE 60.32
  • Support Level
  • DKL $43.55
  • BLTE $59.12
  • Resistance Level
  • DKL $44.81
  • BLTE $62.64
  • Average True Range (ATR)
  • DKL 0.83
  • BLTE 1.78
  • MACD
  • DKL 0.08
  • BLTE 0.32
  • Stochastic Oscillator
  • DKL 71.04
  • BLTE 92.07

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Share on Social Networks: